Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Acupuncture treatment for bortezomib-induced peripheral neuropathy: a case report.

Bao T, Zhang R, Badros A, Lao L.

Pain Res Treat. 2011;2011:920807. doi: 10.1155/2011/920807. Epub 2011 Mar 9.

2.

Multiple myeloma, painful neuropathy, acupuncture?

Zhou Y, Garcia MK, Chang DZ, Chiang J, Lu J, Yi Q, Romaguera J, Delasalle K, Guo Y, Forman A, Fang W, Wang M.

Am J Clin Oncol. 2009 Jun;32(3):319-25. doi: 10.1097/COC.0b013e318173a520. Review.

PMID:
19887992
3.

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.

Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P.

Lancet Oncol. 2010 Nov;11(11):1057-65. doi: 10.1016/S1470-2045(10)70206-0. Epub 2010 Sep 21.

PMID:
20864405
4.

Acupuncture for neuropathic pain due to bortezomib in a patient with multiple myeloma.

Mandıroğlu S, Cevik C, Aylı M.

Acupunct Med. 2014 Apr;32(2):194-6. doi: 10.1136/acupmed-2013-010491. Epub 2014 Jan 3.

PMID:
24389811
5.

Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.

Reece D, Imrie K, Stevens A, Smith CA; Hematology Disease Site Groupof Cancer Care Ontario’s Program in Evidence-based Care.

Curr Oncol. 2006 Oct;13(5):160-72.

6.

Impact of dose modification on intravenous bortezomib-induced peripheral neuropathy in multiple myeloma patients.

Cho J, Kang D, Lee JY, Kim K, Kim SJ.

Support Care Cancer. 2014 Oct;22(10):2669-75. doi: 10.1007/s00520-014-2256-6. Epub 2014 Apr 26.

PMID:
24771302
7.

A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment.

Mauermann ML, Blumenreich MS, Dispenzieri A, Staff NP.

Muscle Nerve. 2012 Dec;46(6):970-7. doi: 10.1002/mus.23493.

PMID:
23225391
8.

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.

Corthals SL, Kuiper R, Johnson DC, Sonneveld P, Hajek R, van der Holt B, Magrangeas F, Goldschmidt H, Morgan GJ, Avet-Loiseau H.

Haematologica. 2011 Nov;96(11):1728-32. doi: 10.3324/haematol.2011.041434. Epub 2011 Jul 26.

9.

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA.

J Clin Oncol. 2009 Jul 20;27(21):3518-25. doi: 10.1200/JCO.2008.18.3087. Epub 2009 Jun 15.

10.

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA.

J Clin Oncol. 2006 Jul 1;24(19):3113-20. Epub 2006 Jun 5.

PMID:
16754936
11.

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

Argyriou AA, Iconomou G, Kalofonos HP.

Blood. 2008 Sep 1;112(5):1593-9. doi: 10.1182/blood-2008-04-149385. Epub 2008 Jun 23. Review. Erratum in: Blood. 2009 Apr 30;113(18):4478.

12.

Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy.

Zheng H, Xiao WH, Bennett GJ.

Exp Neurol. 2012 Dec;238(2):225-34. doi: 10.1016/j.expneurol.2012.08.023. Epub 2012 Aug 28.

PMID:
22947198
13.

Bortezomib-induced polyneuropathy.

Rampen AJ, Jongen JL, van Heuvel I, Scheltens-de Boer M, Sonneveld P, van den Bent MJ.

Neth J Med. 2013 Apr;71(3):128-33.

14.

The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.

Jung JY, Kim HY, Han B, Choi DR, Zang DY, Kim HJ.

Biomed Res Int. 2014;2014:237698. doi: 10.1155/2014/237698. Epub 2014 Jun 4.

15.

Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.

Iwamoto T, Ishibashi M, Fujieda A, Masuya M, Katayama N, Okuda M.

Pharmacotherapy. 2010 Jul;30(7):661-5. doi: 10.1592/phco.30.7.661.

PMID:
20575631
16.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J.

Br J Haematol. 2009 Mar;144(6):895-903. doi: 10.1111/j.1365-2141.2008.07573.x. Epub 2009 Jan 16.

PMID:
19170677
17.

Inhibition of the neuronal NFκB pathway attenuates bortezomib-induced neuropathy in a mouse model.

Alé A, Bruna J, Calls A, Karamita M, Haralambous S, Probert L, Navarro X, Udina E.

Neurotoxicology. 2016 Jul;55:58-64. doi: 10.1016/j.neuro.2016.05.004. Epub 2016 May 19.

PMID:
27211850
18.

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.

Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M.

J Hematol Oncol. 2014 May 9;7:41. doi: 10.1186/1756-8722-7-41.

19.

Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy.

Jeter A, Kang Y.

Exp Hematol Oncol. 2012 Aug 15;1(1):20. doi: 10.1186/2162-3619-1-20.

20.

Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.

Koh Y, Lee SY, Kim I, Kwon JH, Yoon SS, Park S, Chung MH, Suh SY, Kim KS, Kim HS.

Cancer Chemother Pharmacol. 2014 Sep;74(3):653-7. doi: 10.1007/s00280-014-2555-0. Epub 2014 Aug 6.

PMID:
25096796

Supplemental Content

Support Center